Sanofi S.A., FR0000120578

Sanofi names Tour partner. Sanofi stock trades at EUR 71.52 before October 30 results

Published on 10/16/2026 at 09:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi became a Tour de France partner on October 16, 2026. Sanofi stock was at EUR 71.52 at Lang & Schwarz before October 30 results.

Tour de France and results timeline

Sanofi became a Tour de France partner on October 16, 2026.
Second-quarter net sales rose 17.80 percent to EUR 11.60 billion.
Sanofi stock traded at EUR 71.52 at 9:16 a.m. CEST at Lang & Schwarz on October 16, 2026.

Bauhaus geometric poster with abstract stylized molecular structure in violet and cyan on white background with bold sans-serif PHARMACIE PARIS text — Sanofi FR0000120578 Bauhaus-style poster with abstract molecular structure in violet-cyan-white reading PHARMACIE PARIS, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was at EUR 71.52 at Lang & Schwarz on October 16, 2026, at 9:16 a.m. CEST in pre-market trading. Sanofi's investor-relations page listed a new partnership making the pharmaceutical group a major partner of the Tour de France on the same date, while third-quarter results are scheduled for October 30, 2026.

Tour de France partnership adds visibility

The announcement gives Sanofi a broad public platform ahead of its next financial update. The company presented the Tour de France partnership on October 16, 2026, through its investor-relations channel, which also lists the October 30 results webcast and a November 17 appearance at the Jefferies Global Healthcare Conference.

The partnership is a corporate and brand event rather than a quantified earnings announcement. For the stock, the more immediate test remains the next operating update, because the latest reported quarter combined fast sales growth with acquisition effects and one-off items.

What does the latest growth mean?

In the second quarter of 2026, Sanofi net sales rose 17.80 percent year over year to EUR 11.60 billion, while business earnings per share increased 33.30 percent, according to the Q2 earnings transcript dated July 30, 2026, published by Yahoo Finance. First-half sales increased 15.70 percent, and business earnings per share grew 22.70 percent.

Management also upgraded its full-year 2026 outlook in the July 30 discussion, calling for sales growth of approximately 10 percent at constant exchange rates and business earnings per share growth slightly faster than sales. The comparison matters because Sanofi expects slower growth in the second half against tougher prior-year comparisons.

Key dates for Sanofi investors

Sanofi lists October 30, 2026, for third-quarter results and November 17, 2026, for the Jefferies Global Healthcare Conference. The October webcast is scheduled for 1:30 p.m. CET and will include a management presentation followed by questions from the financial community.

Stock price before the results

Sanofi has a clear near-term calendar: a new Tour de France partnership on October 16, followed by the third-quarter report on October 30. The latest operating figures provide the benchmark for judging whether sales growth and earnings momentum are holding through the second half.

Sanofi was trading at EUR 71.52 at Lang & Schwarz on October 16, 2026, at 9:16 a.m. CEST in pre-market trading. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.